Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of valemetostat monotherapy in relapsed or refractory peripheral T-cell lymphoma
NL-OMON51259Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of valemetostat in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia-lymphoma (ATLL), sponsored by Daiichi Sankyo Co., Ltd. Started Feb 2022; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NL-OMON51259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51259.